Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Product/Service

Debiopharm to Showcase Research Results of Their DDR Inhibitors at the 2024 AACR Conference in San Diego

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standard-of-care to cure cancer and infectious diseases, today announced preclinical data releases for two of their compounds inhibiting the DNA-damage response (DDR) of cancer cells, including Debio 0123 [selective WEE1 inhibitor] and Debio 0432 [Selective USP1 Inhibitor] at the 2024 Annual American Association for Cancer Research (AACR) summit in San Diego, California.

"Since 2017, Debiopharm has been growing its expertise in the DDR inhibitor field, firstly through its WEE1-inhibitor Debio 0123 and through the recently in-licensed asset, targeting USP1. These posters are proof of our commitment to stay at the forefront of DDR-inhibitor development and outsmart hard-to-treat cancers through synthetic lethality or other groundbreaking combinations." - Angela Zubel, Chief Development Officer at Debiopharm

AACR 2024 Poster Presentations

Debiopharm compound



Mon, April 8th
Poster display: 9:00-12:30pm

Abstract #: CT064

Poster Section: 48

Poster Board #: 14

Debio 0123

Impact of food and high gastric pH on the bioavailability of the WEE1 inhibitor Debio 0123 assessed in a

Phase 1 dose escalation study

Anne Bellon, Clinical Pharmacology Lead

Mon, April 8th
Poster display: 1:30-5:00pm

Abstract #: 3370

Poster Section: 29

Poster Board #: 27

Debio 0123

Anti-tumor activity of Debio 0123 in combination with sacituzumab govitecan in preclinical models of breast cancer

Luke Piggott, Principal Scientist

Tue, April 9th
Poster display: 1:30-5:00pm

Abstract #: 6507

Poster Section: 46

Poster Board #: 24

Debio 0123

Simulation driven identification of combination for the WEE1 inhibitor Debio 0123 results in synergistic effect with cabozantinib validated in vivo

Luke Piggott, Principal Scientist

& Turbine AI

Wed, April 10th
Poster display: 9:00-12:30pm

Abstract #: 7145

Poster Section: 23

Poster Board #: 7

Debio 0432

Identification of Debio 0432 as a potent and selective USP1 inhibitor for cancer therapy

Noemie Luong, Associate Principal Scientist


About DNA-Damage Repair (DDR)

When cells have damaged DNA, they need to undergo a repair process called DDR to be able to survive. Cancer cells rely a lot on DDR as they divide and grow uncontrollably. Inhibition of DDR, particularly in combination with other anticancer agents, prevents cancer cells from repairing their DNA, which ultimately activates a self-destruction program in cancer cells. DDR inhibitors such as Debiopharm's WEE1 and USP1 inhibitors, are being tested in clinical and preclinical studies.

Debiopharm's commitment to cancer patients

Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select large pharmaceutical commercialization partners to maximize patient access globally.

Visit us https://www.debiopharm.com/drug-development/

Follow us @DebiopharmNews

These press releases may also interest you

at 01:40
During the COMPUTEX 2024 exhibition from June 4th to 7th, Mnemonic Electronic Co., Ltd. (hereinafter referred to as Mnemonic), Longsys's Taiwan subsidiary, will showcase a series of high-capacity SSD products under the theme "Embracing the Era of...

at 01:12
Max Stock Ltd. (the "Company") announces an AGM to be held at 10:00 AM on June 26, 2024 (date of record: May 28, 2024), at the offices of the Company's external legal counsel Herzog Fox Neeman & Co., 6 Itzhak Sadeh St., Tel Aviv, with the following...

at 01:05
Wolters Kluwer Tax & Accounting (TAA) has launched Twinfield DossierFlow (DossierFlow), a cloud-based solution for the collection of customer information, in the Netherlands. The tool tracks documents sent by clients to support tasks such as...

at 01:00
GCCL, a Korean clinical trial sample analysis company, has introduced Droplet Digital PCR devices (ddPCR) for the first time in the domestic clinical trial sample analysis industry, enhancing its capabilities in...

at 01:00
A new Denmark-based research initiative aims to establish a potential causal link between the gut microbiome ? the combined genetic material of the communities of bacteria and other microbes in the human gut ? and the development of cardiometabolic...

at 01:00
Verkada, a pioneer in cloud-based physical security solutions, announced Ardon Anderson's appointment as Vice President of EMEA. This appointment comes as Verkada is seeing strong sales and partner growth throughout the region....

News published on and distributed by: